Oncology Corporate Profile
Biodesix is a personalized medicine company focused on the development of diagnostic products that inform treatment decisions and improve patient care. The Company’s goal is to give physicians more information about the patient and their disease; understanding the clinically meaningful information contained within each patient’s molecular profile leads to better care and better outcomes. The Company’s unique approach is based on ProTS®, proprietary technology which exploits the power of mass spectrometry and enables the discovery of specific molecular profiles. Biodesix collaborates with clinical investigators to address critical clinical questions, and partners with biotechnology and pharmaceutical companies to develop diagnostics to select patients most likely to benefit from novel therapies.
|VeriStrat??||serum proteomic test||VeriStrat is intended for 2nd and 3rd line advanced non-small cell lung cancer(NSCLC) patients who are eligible for EGFR-TKI therapy.|
View additional information on commercial products here »
|Brand / Product||Class||Area of Study||Phase||Partnership|
|VeriStratt_||serum proteomic test||Colorectal cancer||Development|
|VeriStrat_||serum proteomic test||Squamous cell carcinoma of the Head & Neck||Development|
View additional information on product candidates here »